Table 1.
Doses, routes, and schedules of pharmacological ascorbate administration as a single agent and tumor response.
| Model | Cancer cell (concentration) | Syngeneic or xenograft | Implantation | Tumor volume when treatment started | [VC] | Schedule | Administration | Ascorbate measurement | Tumor response | Reference |
|---|---|---|---|---|---|---|---|---|---|---|
| Ncr-nu/nu | PAN-02 (106) | Xenograft | SC | 30–40 mm3 | 4 g/kg | Daily; until EP | IP | No | Yes | (25) |
| Ncr-nu/nu | 9L (2 × 106) | Xenograft | SC | 25–50 mm3 | 4 g/kg | Daily; until EP | IP | No | Yes | (26) |
| Ovcar5 (5 × 106) | Xenograft | |||||||||
| Pan02 (1 × 106) | Xenograft | |||||||||
| Ncr-nu/nu | MIA PaCa-2 (2 × 106) | Xenograft | SC | 3–4 mm3 | 4 g/kg | Twice daily; 14 days | IP | No | Yes | (7) |
| BALB/c nude | WiDr (8 × 106) | Xenograft | SC | 300–500 mm3 | 0.15 g/kg | Daily; 12 days | IP | No | Yes | (27) |
| SCID | P493-6 (3 × 106) | Xenograft | SC | 7 days BI + AI | 5 g/L | Throughout | PO | No | Yes | (30) |
| SCID | EHMES-10 (5 × 106) | Xenograft | SC | 50 mm3 | 1 M solution | Single infusion | IV | No | Yes | (32) |
| BD2F mice | L1210 ascites (105) | Syngeneic | IP | 1 day AI | 2 g/kg | Daily; until EP | IP | No | No | (33) |
| BALB/C | CT-26 (106) | Syngeneic | IP | From outset | 1.5 g/kg | Every 3 days | IP | No | Yes | (34) |
| NMRI mice | TLT (106) | Syngeneic | IM | 3 days AI | 1 g/kg | Daily; 27 days | IV | Plasma (for PK study) | Yes | (13) |
| Lobund-Wistar rats | PAIII (106) | Syngeneic | SC | 10 days AI | 4 g/kg | Daily; 30 days | IP | No | Yes | (15) |
PO, per os; IV, intravenous; IP, intraperitoneal; SC, subcutaneous; IM, intramuscular; AI, after implantation; BI, before implantation; EP, endpoint; DHA, dehydroascorbic acid.